Clinical Trials

The purpose of our Clinical Development efforts is to accelerate the global adoption of BTG’s therapies for patient benefit.

We have a diverse portfolio of products including medical devices, pharmaceuticals, and drug-device combinations in several therapeutic areas. We continue to invest in clinical trials designed to expand the appropriate uses and geographic availability of our existing products. We also generate data to support bringing innovative new products to market – and to the patients who need them most. We are committed to demonstrating the value of our therapies to patients, physicians, payers and healthcare systems. Apart from demonstrating the safety and efficacy of our therapies, we strive to deliver clinical data able to enhance patient selection and treatment optimization.

In addition to traditional clinical trials, we design and conduct Registries, Retrospective Data Analysis, development of Patient Reported Outcome (PRO) measures and Health Economics Outcomes Research (HEOR).

Take a look at our Clinical Trials*

Interventional Oncology
Product Clinical Trial Title / Identifier Trial Type Primary Indication Purpose
TheraSphere® A TheraSphere® Advanced Dosimetry Retrospective Global Study in HCC (TARGET) NCT03295006 Global Retrospective Study Hepatocellular Carcinoma (HCC) This retrospective, multinational, single-arm study looking at patients who were previously treated with TheraSphere®
Embolics
Product Clinical Trial Title / Identifier Trial Type Primary Indication Purpose
Vandetanib-eluting radiopaque beads Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies (VEROnA) NCT03291379 First in man Hepatocellular Carcinoma (HCC) This is a, open label single arm phase 0 window of opportunity study of vandetanib-eluting radiopaque beads in patients with resectable liver malignancies.
Interventional Pulmonology
Product Clinical Trial Title / Identifier Trial Type Primary Indication Purpose
PneumRx® Coil System** Post Market Observational, Prospective, Multi-center Study NCT01806636 Prospective Post-Market Observational Registry Emphysema This registry is a post market observational, prospective, multi-centre registry. It is designed to evaluate patient experience with the RePneu™ device for the relief of the emphysema symptoms and the continued collection of safety and effectiveness data on this CE Mark product. In addition, the registry will collect information that will serve as the foundation for a cost effectiveness analysis.
PneumRx® Coil System** Study of PneumRx Endobronchial Coil System in Treatment of Subjects With Severe Emphysema (ELEVATE) NCT03360396 European Prospective Randomized Interventional treatment trial Emphysema This study will look at outcomes between Endobronchial Coil Treatment and Control groups in patients with severe heterogeneous and or homogeneous emphysema. heterogeneity in both the Treatment and Control Groups.
Interventional Vascular
Product Clinical Trial Title / Identifier Trial Type Primary Indication Purpose
EKOS® Endovascular System** An International Pulmonary Embolism Registry Using EKOS (KNOCOUT PE) NCT03426124 Global Observational Patient Registry Pulmonary Embolism and Thrombosis This registry is designed to understand acoustic pulse thrombolysis (APT) treatment used as standard of care across globally for pulmonary embolism. The registry will include individuals who have already received the APT treatment and those that will undergo APT treatment
Provensis Ltd. Effect of Varithena on Wound Healing in VLU (VIEW-VLU) NCT03257254 Registry Venous Leg Ulcer This 12 month, multicenter, open-label registry is designed to collect treatment and outcome data related to subjects treated with Varithena for GSV system and/or AASV incompetence resulting in VLU.

*Table only includes studies currently “Recruiting” patients on www.Clinicaltrials.gov or EUdraCT. Last updated 12 December 2018

** PneumRx® Coil is also referred to as RePneu™. EKOS® is also referred to as EkoSonic®.